Advertisement
Advertisement

QURE

QURE logo

uniQure N.V.

9.91
USD
-0.70
-6.58%
Apr 01, 15:59 UTC -4
Closed
exchange

Pre-Market

9.84

-0.07
-0.76%

uniQure N.V. Profile

About

UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands.

Info & Links

CEO

Matthew Kapusta

Headquarters

PAASHEUVELWEG 25
AMSTERDAM, P7 1105 BP, NETHERLANDS

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.uniqure.com

Auditor

KPMG Accountants N.V.

Share holders

3

Employees

209

uniQure N.V. Statistics

Valuation Measures

Market Capitalization2

531.85M

Enterprise Value

424.24M

Enterprise Value/EBITDA(ttm)

-2.47

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

22.10

Price to Book(mrq)

11.31

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

41.06%

Operating Margin(ttm)

-837.80%

Profit Margin(ttm)

-1155.75%

Return on Equity(ttm)

-188.82%

Return on Invested Capital(ttm)

-260.44%

Return on Assets(ttm)

-32.17%

Income Statement

Revenue(ttm)

27.12M

Revenue Per Share(ttm)

0.50

Gross Profit(ttm)

8.79M

EBITDA(ttm)3

-171.65M

Net Income Available to Common(ttm)

-239.56M

Diluted EPS(ttm)

-4.96

Share Statistics

Beta (5Y Monthly)

0.38

52-Week Change

90.21%

S&P 500 52-Week Change

8.21%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

54.08M

Dividend Yield

0.00%

Float4

46.43M

% Held by Insiders

4.74%

% Held by Institutions

78.83%

Balance Sheet

Total Cash(mrq)

367.52M

Total Cash Per Share(mrq)

6.80

Total Debt(mrq)

51.32M

Total Debt/Equity(mrq)

-760.13%

Current Ratio(mrq)

9.74%

Quick Ratio(mrq)

6.51%

Book Value Per Share(mrq)

-0.14

Cash Flow

Operating Cash Flow Per Share(ytd)

-3.76

Free Cash Flow(ytd)

-186.10M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement